Comparison · NCT05222555-63f9a887
Tafasitamab Dose Level 1 + 25 mg Lenalidomide vs Tafasitamab Dose Level 2 + 25 mg Lenalidomide: Number of Participants With Any ≥Grade 3 TEAE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tafasitamab Dose Level 1 + 25 mg Lenalidomide vs Tafasitamab Dose Level 2 + 25 mg Lenalidomide: Number of Participants With Any ≥Grade 3 TEAE. Trial comparisons, record NCT05222555-63f9a887. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05222555-63f9a887
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.833 | 0.436 | 0.97 | wilson | |
| Risk in group 2 | 0.809 | 0.675 | 0.896 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0248 | -0.382 | 0.216 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.702 | 1.51 | log | |
| Odds ratio, group 1 over group 2 | 1.18 | 0.123 | 11.4 | log | |
| Number needed to treat, for one more participant with the outcome on Tafasitamab Dose Level 1 + 25 mg Lenalidomide than on Tafasitamab Dose Level 2 + 25 mg Lenalidomide | 40.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tafasitamab Dose Level 1 + 25 mg Lenalidomide | Tafasitamab was administered as an intravenous (IV) infusion in 28-day cycles until disease progression, unacceptable toxicity, or other criteria for treatment discontinuation were met. Lenalidomide 25 mg was administered once daily (QD) orally on Days 1 to 21 of each 28-day cycle for up to 12 cycles or until criteria for treatment discontinuation were met. Following discontinuation of lenalidomide, participants continued with tafasitamab monotherapy at the assigned treatment regimen. | 5 | 6 | OG000 |
| Group 2 | Tafasitamab Dose Level 2 + 25 mg Lenalidomide | Tafasitamab was administered as an IV infusion in 28-day cycles until disease progression, unacceptable toxicity, or other criteria for treatment discontinuation were met. Lenalidomide 25 mg was administered QD orally on Days 1 to 21 of each 28-day cycle for up to 12 cycles or until criteria for treatment discontinuation were met. Following discontinuation of lenalidomide, participants continued with tafasitamab monotherapy at the assigned treatment regimen. | 38 | 47 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Any ≥Grade 3 TEAE
- Description
The toxicity grade of TEAEs was graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0) using the following definitions: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2: moderate; minimal; local or non-invasive intervention indicated; limiting age-appropriate instrumental activities of daily living (refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.). Grade 3: severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4: life-threatening consequences; urgent intervention indicated. Grade 5: death related to AE.
- Time frame
- up to approximately 2 years
- Population
- Safety Analysis Set
Source ClinicalTrials.gov
Trial
- Title
- Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients
- NCT number
- NCT05222555
- Phases
- PHASE1, PHASE2
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Tafasitamab, Lenalidomide
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2025-07-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05222555?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05222555-63f9a887